Successful Treatment of Histiocytic Sarcoma in Childhood.

Haroula Tsipou, Georgia Avgerinou, Stavros Glentis, Kalliopi Stefanaki, Antonis Kattamis

Abstract readCase Reports

In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haroula TsipouDivision of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, GRC.

Georgia AvgerinouDivision of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, GRC.

Stavros GlentisDivision of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, GRC.

Kalliopi StefanakiDepartment of Pathology, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, GRC.

Antonis KattamisDivision of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histiocytic sarcoma (HS) is a rare malignant neoplasm that belongs to malignant histiocytoses. HS primarily occurs in adult males and is exceptionally uncommon in pediatric populations. Extranodal regions represent the most common sites of HS manifestation. Diagnosis necessitates histopathological evidence of neoplasm, along with verification of cellular origin through specialized studies. Here, we describe a case of a three-year-old female toddler with HS in her calf that was successfully treated with the chemotherapy protocol of Langerhans Cell Histiocytosis (LCH)-IV, the International Collaborative Treatment Protocol for Children and Adolescents with LCH, version 1.3.

Indexed as

chemotherapychildrenhistiocytic sarcomaimmunochemistrylangerhans cell histiocytosis (lch)

Identifiers

PMID41835761

DOI10.7759/cureus.103409

PMCPMC12983415

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.